A drenal disorders and non-alcoholic fatty liver disease

被引:24
|
作者
Papanastasiou, Labrini [1 ,2 ]
Fountoulakis, Stelios [1 ,2 ]
Vatalas, Ioannis-Anastasios [3 ]
机构
[1] G Gennimatas Gen Hosp, Dept Endocrinol, 154 Mesog Ave, Athens 11527, Greece
[2] G Gennimatas Gen Hosp, Diabet Ctr, 154 Mesog Ave, Athens 11527, Greece
[3] Univ Athens, Med Sch, Unit Translat Med & Clin Res Endocrinol, Athens, Greece
关键词
Adrenal glands; Non-alcoholic fatty liver disease; Glucocorticoids; Aldosterone; Dehydroepiandrosterone; Catecholamines; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; HEPATIC INSULIN SENSITIVITY; RENIN-ANGIOTENSIN SYSTEM; GLUCOCORTICOID-RECEPTOR; METABOLIC SYNDROME; SEVERE STEATOHEPATITIS; ADRENAL INSUFFICIENCY; PREDNISOLONE THERAPY; CORTISOL SECRETION; CIRCULATING LEVELS;
D O I
10.23736/S0391-1977.16.02583-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the developed world and its pathogenesis is complex and multifactorial. It is considered the hepatic manifestation of the metabolic syndrome and is the leading cause of hepatic cirrhosis. This review aims to present current knowledge on the involvement of the adrenal glands in the development of NAFLD. Clinical and animal studies have shown that excess glucocorticoids (GC) have been implicated in the pathogenesis of NAFLD. Patients with NAFLD seem to have a subtle chronic activation of the hypothalamic pituitary adrenal axis leading to a state of subclinical hypercortisolism. Regulators of GC such as 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1), an enzyme that regenerates cortisol from inactive cortisone, and 5a/5 beta-reductases, enzymes that increase cortisol clearance, are implicated in the development of NAFLD by amplifying local GC action. Adrenal androgen (dehydroepiandrosterone) abnormalities and increased aldosterone levels may also have a role in the development of NAFLD whereas the contribution of adrenergic signaling in NAFLD pathogenesis remains unclear.
引用
收藏
页码:151 / 163
页数:13
相关论文
共 50 条
  • [41] Liver transplantation and non-alcoholic fatty liver disease
    Petros Zezos
    Eberhard L Renner
    World Journal of Gastroenterology, 2014, (42) : 15532 - 15538
  • [42] Sex difference in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Tomiya, Tomoaki
    HEPATOLOGY RESEARCH, 2010, 40 (01) : 108 - 110
  • [43] Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
    Wu, Dongqing
    Zhu, Huaqing
    Wang, Hua
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [44] PTEN in Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis and Cancer
    Peyrou, Marion
    Bourgoin, Lucie
    Foti, Michelangelo
    DIGESTIVE DISEASES, 2010, 28 (01) : 236 - 246
  • [45] CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Sila Cocciolillo
    Giustino Parruti
    Leonardo Marzio
    World Journal of Hepatology, 2014, (07) : 496 - 503
  • [46] Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Stavropoulos, Konstantinos
    Imprialos, Konstantinos
    Pittaras, Andreas
    Faselis, Charles
    Narayan, Puneet
    Kokkinos, Peter
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (03) : 239 - 245
  • [47] Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic steatohepatitis - NASH
    Keller, KM
    MONATSSCHRIFT KINDERHEILKUNDE, 2004, 152 (08) : 864 - 869
  • [48] An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (08) : 759 - 772
  • [49] Surgical Treatment of Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease
    Weiner, R. A.
    DIGESTIVE DISEASES, 2010, 28 (01) : 274 - 279
  • [50] Pathology of non-alcoholic fatty liver disease
    Bedossa, Pierre
    LIVER INTERNATIONAL, 2017, 37 : 85 - 89